Business
XpresSpa Signs Contract with JFK International Air Terminal LLC for COVID-19 Screening and Testing Location
Working with the Port Authority of New York and New Jersey on Site Selection to Expand Testing to Other Locations Announces Brand Launch of XpresCheck, Which
About this update from Xwell, Inc.
[{"type":"text","content":"Working with the Port Authority of New York and New Jersey on Site Selection to Expand Testing to Other Locations\n Announces Brand Launch of XpresCheck, Which Will Operate Under Company’s XpresTest Subsidiary NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today provided a business update related to its objective of pursuing COVID-19 screening and testing in convenient and accessible locations at U.S. airports. The Company is pleased to announce that it has signed a contract with JFK International Air Terminal LLC (“JFKIAT”) to pilot test its concept of providing diagnostic COVID-19 tests located in Terminal 4. To facilitate the JFK pilot test, the Company has signed an agreement with JFKIAT for a new modular constructed testing facility within the terminal. The site will host nine separate testing rooms with a capacity to administer over 500 tests per day. The Company intends to offer its services to airline employees, contractors and workers, concessionaires and their employees, TSA officers, and U.S. Customs and Border Protection agents. All COVID-19 screening and testing will be conducted by a newly launched brand, XpresCheck™, which will operate under the Company’s XpresTest® subsidiary. The Company is also working closely with the Port Authority of New York and New Jersey to bring XpresCheck locations to other locations. A formal announcement with additional details is expected to be made in the coming weeks in conjunction with the Port Authority of New York and New Jersey and JFKIAT. In addition, the Company is in discussions with other U.S. airports regarding the temporary conversions of existing XpresSpa locations into XpresCheck testing sites as it looks to roll out this concept further. The Company also announced the launch of XpresCheck, the operating brand under which the Company’s previously formed XpresTest subsidiary will screen and test for COVID-19. Although the JFK pilot test site will be in a newly constructed modular facility, the Company is discussing temporary conversions of existing XpresSpa locations into XpresCheck testing sites as it looks to roll out this concept to other U.S. airports. Doug Satzman, XpresSpa CEO, stated, \"We are thrilled to be in a position to launch our first pilot test at JFK Terminal 4 a...